Compare Etsy Inc (ETSY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs ResMed Inc. — how do they compare? Etsy Inc trades at $84.44 (market cap $8.14B), while ResMed Inc. trades at $202.22 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 3.5× Etsy Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Etsy Inc pays none. Which is the better fit depends on your goals.
| ETSY | RMD | |
|---|---|---|
Market Cap | $8.14B | $28.80B |
Sector | Consumer Cyclical | Health |
52-Week High | $85.74 | $293.73 |
52-Week Low | $44.05 | $182.82 |
Enterprise Value | $9.79B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Etsy stock trades at $83.06, up 3.14% recently and showing strong technical momentum with bullish moving average signals. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $0.89 surpassing the $0.62 estimate. However, valuation metrics appear elevated with a P/E of 32.85 and P/B of 52.12, while the company maintains strong gross margins of 71.55% and positive operating cash flow of $693.41M in 2025.
The outlook is mixed with improving buyer momentum and AI-driven engagement tools supporting growth, but active buyer declines and high debt levels present risks. Analyst sentiment leans positive with 22 buy ratings versus 3 sells, though the consensus price target of $72.38 suggests 13% downside from current levels. The Depop divestiture to eBay removes a distraction, allowing focus on core marketplace improvements.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
